|
|
Post by dh4mizzou on Dec 27, 2022 7:05:48 GMT -5
I haven't heard a word about Brazil for a long while.
|
|
|
|
Post by Thundersnow on Dec 27, 2022 10:05:13 GMT -5
I haven't heard a word about Brazil for a long while. They had to shutdown operations because of COVID. MNKD and BIOMM is in the process of petitioning the Healthcare authorities to extend the shelf life of Afrezza from 12 months to 36 months. Apparently BIOMM had to destroy inventory because of expiration. Hopefully they will get approval and get back on track. COVID really decimated the country and selling Afrezza was non existent. This will also help the margins for MNKD. |
|
|
|
Post by neil36 on Nov 13, 2024 8:23:18 GMT -5
Biomm S.A., in compliance with the provisions of CVM Resolution No. 44 of August 23, 2021, hereby informs its shareholders and the market in general that today it entered into an agreement with Gan&Lee Pharmaceuticals (“Gan&Lee”) for the marketing and distribution of the drug insulin aspart in Brazil.
Insulin aspart is an ultra-fast-acting insulin analogue indicated for the treatment of diabetes mellitus. The product can be used in combination with intermediate- or long-acting insulins and complements Biomm's portfolio of solutions for diabetic patients.
Click here to access the full Material Fact.
Nova Lima/MG, November 13, 2024
|
|
|
|
Post by prcgorman2 on Nov 13, 2024 8:49:59 GMT -5
Can you provide a link? My Google searches didn’t locate the story. Instead they made me question whether the “ultra-rapid analogue” being referred to was something like Lispro, and not Afrezza.
|
|
|
|
Post by neil36 on Nov 13, 2024 8:53:24 GMT -5
Can you provide a link? My Google searches didn’t locate the story. Instead they made me question whether the “ultra-rapid analogue” being referred to was something like Lispro, and not Afrezza. I signed up for the BIOMM email updates years ago. They come in Portugese. I copy it into Google translate. |
|
|
|
Post by agedhippie on Nov 13, 2024 8:59:03 GMT -5
Can you provide a link? My Google searches didn’t locate the story. Instead they made me question whether the “ultra-rapid analogue” being referred to was something like Lispro, and not Afrezza. Gan & Lee make a Novolog (Aspart) biosimilar insulin and I suspect that is what they are talking about. Ultra-rapid is definitely pushing the description though as the manufacturers just refer to it as fast-acting insulin. |
|
